Osemitamab

Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI) . Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study[1][2].

Product Specifications

CAS Number

[2460539-61-9]

Product Name Alternative

TST001

UNSPSC

12352203

Target

Gap Junction Protein

Type

Inhibitory Antibodies

Related Pathways

Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/osemitamab.html

Purity

99.43

Solubility

10 mM in DMSO|H2O

Smiles

[Osemitamab]

Molecular Weight

(146.5 kDa)

References & Citations

[1]Shen L, et al. Osemitamab in combination with capecitabine and oxaliplatin (CAPOX) as a first line treatment of advanced G/GEJ cancer: Updated data of cohort C from a phase I/IIa, multi-center study (TranStar102/TST001-1002) [J]. 2023.|[2]Park Soon Jae, et al. Pharmaceutical composition comprising human hyaluronidase PH20 variants for drug delivery system via subcutaneous injection. World Intellectual Property Organization, WO2023075506 A1. 2023-05-04.|[3]X. Qian, et al., 1560P Osemitamab (TST001) : An ADCC enhanced humanized anti-CLDN18.2 mab, demonstrated improved efficacy in combination with anti-PD-L1/PD-1 mab and oxaliplatin/5-FU in preclinical tumor models. Annals of Oncology, 34 (2), S873, 2023.